Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BPL-1357 Influenza Vaccine
NCT05027932Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BPL-1357 in influenza (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Type and severity of adverse events at Day 56 and Type of serious adverse events at Day 56. Started Jun 2022; status: completed.
02
Drugs
BPL-1357
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05027932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027932.